US 2024/0190985 A1 · THERAPEUTIC CD99 ANTIBODIES

Abstract

The present disclosure relates to an antibody-based molecule that binds CD99. This antibody-based molecule comprises a heavy chain variable region having: (i) a complementarity—determining region 1 (CDR-H1) comprising an amino acid sequence of any one of SEQ ID NOs: 1-3, or a modified amino acid sequence of any one of SEQ ID NOs: 1-3; (ii) a complementarity—determining region 2 (CDR-H2) comprising an amino acid sequence of any one of SEQ ID NOs: 4-10, or a modified amino acid sequence of any one of SEQ ID NOs: 4-10; and/or (iii) a complementarity—determining region 3 (CDR-H3) comprising an amino acid sequence of any one of SEQ ID NOs: 11-14, or a modified amino acid sequence of any one of SEQ ID NO: 11-14. Also disclosed are isolated polynucleotides encoding the antibody-based molecules, vectors comprising said isolated polynucleotides, as well as pharmaceutical compositions comprising the same and methods of use thereof.

Claims40

Dependent claims

An antibody-based molecule that binds CD99, said antibody-based molecule comprising a heavy chain variable region, wherein said heavy chain variable region comprises:

(i) a complementarity-determining region 1 (CDR-H1) comprising an amino acid sequence of any one of SEQ ID NOs:
1-3, or a modified amino acid sequence of any one of SEQ ID NOs:
1-3, said modified sequence having at least 80% sequence identity to any one of SEQ ID NOs:
1-3;
(ii) a complementarity-determining region 2 (CDR-H2) comprising an amino acid sequence of any one of SEQ ID NOs:
4-10, or a modified amino acid sequence of any one of SEQ ID NOs:
4-10, said modified sequences having at least 80% sequence identity to any one of SEQ ID NOs:
4-10;
and/or
(iii) a complementarity-determining region 3 (CDR-H3) comprising an amino acid sequence of any one of SEQ ID NOs:
11-14, or a modified amino acid sequence of any one of SEQ ID NO:
11-14, said modified sequence having at least 80% sequence identity to any one of SEQ ID NOs:
11-14.

10 more elements

An antibody-based molecule that binds CD99, said antibody-based molecule comprising one or more amino acid modifications to a heavy chain framework region that enhance stability of the antibody-based molecule that binds CD99, wherein said heavy chain framework region comprises the partial amino acid sequence of:

QVQLQQSGPVLVKPGQTLSLTCAISGDSIS (SEQ ID NO:
54), and
further comprises:
(i) a complementarity-determining region 1 (CDR-H1) comprising an amino acid sequence of any one of SEQ ID NOs:
1-3, or a modified amino acid sequence of any one of SEQ ID NOs:
1-3, said modified sequence having at least 80% sequence identity to any one of SEQ ID NOs:
1-3;
(ii) a complementarity-determining region 2 (CDR-H2) comprising an amino acid sequence of any one of SEQ ID NOs:
4-10, or a modified amino acid sequence of any one of SEQ ID NOs:
4-10, said modified sequences having at least 80% sequence identity to any one of SEQ ID NOs:
4-10;
and/or
(iii) a complementarity-determining region 3 (CDR-H3) comprising an amino acid sequence of any one of SEQ ID NOs:
11-14, or a modified amino acid sequence of any one of SEQ ID NO:
11-14, said modified sequence having at least 80% sequence identity to any one of SEQ ID NOs:
11-14.

13 more elements

Dependencies are inferred from the claim text.

Therapeutic cd99 antibodies

Life of this patent

Therapeutic cd99 antibodies

Life of this patent

Abstract

Claims40